Department of Neurology, Chinese PLA General Hospital, Beijing, China.
Lilly Suzhou Pharmaceutical Co., Ltd. Shanghai Branch, 19F, Centre T1, HKRI Taikoo, No. 288, Shimen No.1 Road, Shanghai, 200021, China.
J Headache Pain. 2020 May 13;21(1):53. doi: 10.1186/s10194-020-01117-2.
Adult migraine remains underdiagnosed and undertreated, despite significant negative effects on physical and emotional functioning. Information on prescribing patterns and treatment costs of migraine in China is limited.
This retrospective analysis of the China Health Insurance Research Association (CHIRA) medical insurance claims database in 2016 to 2017 evaluated treatment patterns, direct medical costs, and healthcare resource utilization among adults with migraine in mainland China.
Of 108,375 patients with headache-related outpatient visits, 10,652 were adults with migraine (mean age 51.4 years, 55.4% female). Common comorbidities were major depressive disorder (4.1%), insomnia (3.8%), and anxiety (2.3%). Migraine patients were prescribed acute medication (26.4%), preventive medication (15.0%), and Chinese patent and herbal medicines (24.5% and 11.7%, respectively). Of patients prescribed acute medication, 68.8% received non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs), 7.1% received opioids, while only 3.3% received triptans. Mean annual outpatient costs per patient were 46.5 United States dollars (USD), with mean (standard deviation) 1.8 (2.0) outpatient visits per year. Medication costs for traditional Chinese medicine (22.4 USD per patient) were higher than for Western medicine (13.5 USD).
Among migraine patients in China, NSAIDs were commonly prescribed as acute medication, while utilization of migraine-specific triptans and preventive medications was low.
尽管偏头痛对身体和情绪功能有重大负面影响，但成年人偏头痛仍未得到充分诊断和治疗。有关中国偏头痛处方模式和治疗费用的信息有限。
本研究回顾性分析了中国健康保险研究协会（CHIRA）2016 年至 2017 年的医疗保险理赔数据库，评估了中国大陆偏头痛成年患者的治疗模式、直接医疗费用和医疗资源利用情况。
在 108375 例与头痛相关的门诊患者中，有 10652 例是偏头痛成年人（平均年龄 51.4 岁，55.4%为女性）。常见合并症包括重度抑郁症（4.1%）、失眠（3.8%）和焦虑症（2.3%）。偏头痛患者被处方急性药物（26.4%）、预防药物（15.0%）和中药和草药（分别为 24.5%和 11.7%）。在接受急性药物治疗的患者中，68.8%接受非阿司匹林非甾体抗炎药（NSAIDs），7.1%接受阿片类药物，而只有 3.3%接受曲普坦类药物。每位患者的年门诊费用为 46.5 美元（USD），每年平均（标准差）有 1.8（2.0）次门诊就诊。中药（每位患者 22.4 美元）的药物费用高于西药（每位患者 13.5 美元）。
在中国偏头痛患者中，NSAIDs 通常被用作急性药物，而偏头痛特异性曲普坦类药物和预防药物的利用率较低。
